Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy

ERYILMAZ M. K., Mutlu H., SALIM D. K., MUSRI F. Y., Tural D., Bassorgun I., ...Daha Fazla

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.22, sa.3, ss.533-536, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1177/1078155215572930
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.533-536
  • Anahtar Kelimeler: Melanoma, ipilimumab, cytotoxic T-lymphocyte antigen-4, radiotherapy, dermatitis, RADIATION-THERAPY, LOCAL RADIATION, HIGH-RISK, ADJUVANT RADIOTHERAPY, MELANOMA, INHIBITION, LYMPHADENECTOMY, IMMUNOTHERAPY, ANTIBODY, PATIENT
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.